Medicare Physician Payment Reform Bill Offers Opportunity For Biopharma Input
This article was originally published in The Pink Sheet Daily
Legislation to replace Medicare’s sustainable growth rate formula with value-based physician pay, being jointly developed by the Senate Finance Committee and House Ways and Means Committee, could be a vehicle for the biopharma industry to seek inclusion of drug-friendly policies. The committees released their discussion draft for SGR reform Oct. 31.
You may also be interested in...
In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.